Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 550 of 591 entries
View as:

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06910761 Org: User:
Start: 09/24/25 End: 10/02/28 Due: 10/02/29

Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study

Phase: N/A Priority: Normal
NCT ID: NCT04537871 Org: User:
Start: 11/18/20 End: 06/04/25 Due: 06/04/26

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03011814 Org: User:
Start: 03/08/17 End: 07/14/26 Due: 07/14/27

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03884998 Org: User:
Start: 02/26/19 End: 07/16/25 Due: 07/16/26

Computed Tomography and Biomarker Analysis in Diagnosing Coronary Artery Disease in Asymptomatic Patients Who Have Undergone Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT02077218 Org: User:
Start: 02/28/14 End: 04/30/15 Due: 04/30/16

Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers

Phase: N/A Priority: Normal
NCT ID: NCT02243748 Org: User:
Start: 02/28/15 End: 04/22/19 Due: 04/22/20

Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease

Phase: N/A Priority: Normal
NCT ID: NCT03865992 Org: User:
Start: 03/04/19 End: 10/17/25 Due: 10/17/26

Psycho-Educational Program in Increasing Knowledge and Satisfaction and Decreasing Distress in Younger Patients With Cancer Receiving Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01817335 Org: User:
Start: 08/31/13 End: 05/31/15 Due: 05/31/16

Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00686218 Org: User:
Start: 05/31/08 End: 08/31/14 Due: 08/31/15

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT05384756 Org: User:
Start: 07/13/22 End: 12/01/26 Due: 12/01/27

Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus

Phase: N/A Priority: Normal
NCT ID: NCT01941056 Org: User:
Start: 01/05/14 End: 07/28/17 Due: 07/28/18

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02528877 Org: User:
Start: 11/30/15 End: - Due: -

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00695409 Org: User:
Start: 03/18/08 End: 03/27/17 Due: 03/27/18

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT02208362 Org: User:
Start: 05/18/15 End: 07/08/25 Due: 07/08/26

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01093612 Org: User:
Start: 03/16/11 End: 08/26/25 Due: 08/26/26

Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00005857 Org: User:
Start: 08/31/00 End: 10/31/02 Due: 10/31/03

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06454383 Org: User:
Start: 05/13/24 End: 11/13/26 Due: 11/13/27

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01234740 Org: User:
Start: 12/31/10 End: 03/31/13 Due: 03/31/14

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03712202 Org: User:
Start: 11/28/18 End: 12/23/24 Due: 12/23/25

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT06128070 Org: User:
Start: 07/16/24 End: 11/22/30 Due: 11/22/31

Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01231399 Org: User:
Start: 02/29/12 End: 07/31/16 Due: 07/31/17

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06054776 Org: User:
Start: 12/02/24 End: 10/16/26 Due: 10/16/27

Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01967862 Org: User:
Start: 12/31/13 End: 09/17/18 Due: 09/17/19

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03477396 Org: User:
Start: 06/14/18 End: 06/05/23 Due: 06/05/24

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Phase: N/A Priority: Normal
NCT ID: NCT00825201 Org: User:
Start: 01/31/09 End: 01/16/18 Due: 01/16/19